3129-42-8

Basic information

• Product Name: 4-Androstene-3-one-17beta-carboxylic acid
• Synonyms: 4-Androstene-3-one-17beta-carboxylic acid;testosterone formate
• CAS NO: 3129-42-8
• Molecular Formula: C₂₀H₂₈O₃
• Molecular Weight: 316.43
• Mol File: 3129-42-8.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 395.85°C (rough estimate)
• Flash Point: 190.9°C
• Appearance: /
• Density: 1.1093 (rough estimate)
• Vapor Pressure: 7.23E-08mmHg at 25°C
• Refractive Index: 1.4618 (estimate)
• Water Solubility: 4.395mg/L(25 oC)
• CAS DataBase Reference: 4-Androstene-3-one-17beta-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Androstene-3-one-17beta-carboxylic acid(3129-42-8)
• EPA Substance Registry System: 4-Androstene-3-one-17beta-carboxylic acid(3129-42-8)

Safety Data

• Hazardous Substances Data: 3129-42-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C20H28O3/c1-19-9-7-14(22)11-13(19)3-4-15-16-5-6-18(23-12-21)20(16,2)10-8-17(15)19/h11-12,15-18H,3-10H2,1-2H3/t15-,16-,17-,18-,19-,20-/m0/s1

Upstream product

• 51505-53-4 17β-Chloroacetylandrost-4-en-3-one 
• 58-22-0 testosterone 
• 76920-41-7 3-oxo-androst-4-en-17β-yl Se-phenyl selenocarbonate 
• 44205-36-9 N-(chloromethylidene) N-methylmethanaminium 
• 64-18-6 formic acid 

Relevant articles and documents

Iridium-catalysed highly selective reduction-elimination of steroidal 4-en-3-ones to 3,5-dienes in water

Steroidal 3,5-diene is an important structural motif in steroid drugs. In this report, an iridium-catalyzed reduction-elimination of readily available steroidal 4-en-3-ones is realized to prepare steroidal 3,5-dienes. At a low catalyst loading (S/C = 200), heating 4-en-3-ones in a water-mixed organic solvent with formic acid without inert atmosphere protection afforded the desired 3,5-dienes in moderate to excellent yields. In a gram-scale preparation, recrystallization is used instead of column chromatography to purify products. Excellent functionality tolerance and regioselectivity are featured. Structural moieties such as alkanols (primary, secondary and tertiary), esters (except for formate), tolylates, and ketones (endocyclic or exocyclic) are not affected. Surprisingly, the reduction-elimination only takes place at A-ring 4-en-3-ones. In addition, bicyclic 4-en-3-ones are also viable substrates. Synthetic applications of steroidal 3,5-dienes are demonstrated. Our method can also lead to steroidal 3,5-dienes-3-d (>99% d-incorporation) when DCO2D and D2O are used together.

Use of aromatase-inhibitors for prophylaxis and/or treatment of benign prostatic hyperplasia

Aromatase-inhibitors are used in a method of prophylaxis and/or treatment by therapy of prostatic hyperplasia. Pharmaceutical preparations suitable for such a use comprise an aromatase-inhibitor. A particularly preferred aromatase-inhibitor is, for example, testolactone.